✦ LIBER ✦

Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders

✍ Scribed by Levy-Clarke, Grace; Jabs, Douglas A.; Read, Russell W.; Rosenbaum, James T.; Vitale, Albert; Van Gelder, Russell N.

Book ID: 121429641
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 477 KB
Volume: 121
Category: Article
ISSN: 0161-6420
DOI: 10.1016/j.ophtha.2013.09.048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Levy-Clarke et al.: Expert panel rec

Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96)

✍ Onal, Sumru; Tugal-Tutkun, Ilknur 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Guidelines for the use of immunosuppress

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel

✍ Douglas A. Jabs; James T. Rosenbaum; C.Stephen Foster; Gary N. Holland; Glenn J. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 312 KB

Guidelines for the use of immunosuppress

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel

✍ Douglas A Jabs; James T Rosenbaum 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Tight control is important in patients w

Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1

✍ Hiroshige Sano; Katsumitsu Arai; Takehiro Murai; Junichi Fujisawa; Naoki Kondo; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 181 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt

Differences in the incidence of flares o

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co